Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7372-7376

  Levitt, Randy J ^a   Pollak, Michael ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; ISOENZYMES; MEMBRANE PROTEINS; NITROBENZENES; PANCREATIC NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0037115650     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Prescott. S. M., and Fitzpatrick, F. A. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta, 1470: M69-78, 2000.
2. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois, R. N. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.
3. Half, E., Tang, X. M., Gwyn, K., Sahin, A., Wathen, K., and Sinicrope, F. A. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res., 62: 1676-1681, 2002.
4. Hsu, A. L., Ching, T. T., Wang, D. S., Song, X., and Rangnekar, V. M., and Chen, C. S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem., 275: 11397-11403, 2000.
5. Li, M., Wu, X., and Xu, X. C. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin. Cancer Res., 7: 1010-1016, 2001.
6. Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J., Beauchamp, R. D., and DuBois, R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Investig., 99: 2254-2259, 1997.
7. Alshafie, G. A., Abou-Issa, H. M., Seibert, K., and Harris, R. E. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol. Rep., 7: 1377-1381, 2000.
8. Raz, A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem. Pharmacol., 63: 343-347, 2002.
9. Williams, C. S., Watson, A. J., Sheng, H., Helou, R., Shao, J., and DuBois, R. N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res., 60: 6045-6051, 2000.
10. Chang, H. C., and Weng, C. F. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol. Rep., 8: 1321-1325, 2001.
11. Yip-Schneider, M. T., Barnard, D. S., Billings, S. D., Cheng, L., Heilman, D. K., Lin, A., Marshall, S. J., Crowell, P. L., Marshall, M. S., and Sweeney, C. J. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis (Lond.), 21: 139-146, 2000.
12. Molina, M. A., Sitja-Arnau, M., Lemoine, M. G., Frazier, M. L., and Sinicrope, F. A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res., 59: 4356-4362, 1999.
13. Tucker, O. N., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., Soslow, R. A., Masferrer, J. L., Woerner, B. M., Koki, A. T., and Fahey, T. J., III. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res., 59: 987-990, 1999.
14. Yip-Schneider, M. T., Sweeney, C. J., Jung, S. H., Crowell, P. L., and Marshall, M. S. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J. Pharmacol. Exp. Ther., 298: 976-985, 2001.
15. Hwa, V., Oh, Y., and Rosenfeld, R. G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev., 20: 761-787, 1999.
16. Rubin, R., and Baserga, R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab. Investig., 73: 311-331, 1995.
17. Gooch, J. L., Van Den Berg, C. L., and Yee, D. Insulin-like growth factor-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and antiapoptotic effects. Breast Cancer Res. Treat., 56: 1-10, 1999.
18. Remacle-Bonnet, M. M., Garrouste, F. L., Heller, S., Andre, F., Marvaldi, J. L., and Pommier, G. J. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor a-induced mitogen-activated protein kinase and nuclear factor κB signaling pathways. Cancer Res., 60: 2007-2017, 2000.
19. Testa, J. R., and Bellacosa, A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA, 98: 10983-10985, 2001.